AbbVie's Lutikizumab Hits Late-Stage Endpoints in Hidradenitis Suppurativa
ABBV sits 49% above its 52-week low of $190.75 on light trading volume (0.3× avg).
Summary
AbbVie reported positive late-stage results for lutikizumab in hidradenitis suppurativa, a chronic inflammatory skin condition with limited treatment options, with the drug reducing lesions in the trial and the company eyeing a weight-loss combination. The readout adds a potential new growth driver to an immunology franchise already carried by Skyrizi and Rinvoq, which drove Q2 revenue up 10% to $16.99B. It extends a strong run of pipeline news: etentamig met both primary endpoints in the Phase 3 CERVINO myeloma trial in September, atogepant hit endpoints in menstrual migraine prevention, and the FDA approved JUVMO (tavapadon) for Parkinson's on September 28. The stock is trading near its 52-week high, so the bar for incremental pipeline wins is higher than usual. Details on effect size and the regulatory filing timeline were not disclosed in the headline.
At the time of this announcement, ABBV was trading at $284.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $501.9B. The 52-week trading range was $190.75 to $291.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.